<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01898611</url>
  </required_header>
  <id_info>
    <org_study_id>818192</org_study_id>
    <nct_id>NCT01898611</nct_id>
  </id_info>
  <brief_title>Ghrelin Plus Strength Training in Frail Elderly Study</brief_title>
  <official_title>Ghrelin Plus Strength Training in Frail Elderly Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Frailty is a geriatric syndrome leading to physical deterioration including muscle wasting
      (sarcopenia) and unintentional weight loss. There are currently no approved therapies for
      frailty. Ghrelin is a hormone produced by the stomach that stimulates appetite centers in the
      brain. The investigators already know that a single dose of Ghrelin improves food intake
      immediately after the dose in frail older people. In addition, exercise programs have been
      shown to improve strength and function in older people. In this study, the investigators are
      trying to find out if a joint intervention of ghrelin and resistance training will improve
      walking, balance and leg strength in frail elderly people.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2013</start_date>
  <completion_date type="Actual">August 31, 2016</completion_date>
  <primary_completion_date type="Actual">August 31, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Short Physical Performance Battery (SPPB)</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>The SPPB includes three components: gait speed on a 15-foot walk, standing balance testing, and time to rise from a chair 5 times. Each test is rated on a five-level categorical score, with 0 representing inability to complete the test and 4 representing the highest level of performance, and summed to create a score ranging from 0 to 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-associated Adverse Events</measure>
    <time_frame>Twelve weeks</time_frame>
    <description>Treatment-associated emergent adverse events, including clinically meaningful changes in laboratory measurements (IGF-1, HbA1c, fasting blood glucose, fasting insulin).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>Baseline to twelve weeks</time_frame>
    <description>Change in weight from baseline to 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lean Body Mass</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Total lean body mass by dual energy x-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Muscle Strength</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>One repetition max bench press</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Food Intake</measure>
    <time_frame>Baseline to 12 weeks.</time_frame>
    <description>Change in food intake by 3-day food intake record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>Baseline to 12 weeks.</time_frame>
    <description>Quality of life as assessed by short form 36 (SF-36), higher score indicates better quality of life, scale is 0-100 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Frailty Status</measure>
    <time_frame>Baseline to 12 weeks.</time_frame>
    <description>According to the Fried frailty criteria: Weight loss, exhaustion, low physical activity, slow walking speed, weakness, range 0 to 5, higher score indicates more frailty</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Frailty Syndrome</condition>
  <arm_group>
    <arm_group_label>Ghrelin plus resistance training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ghrelin 7.5 mcg/kg as a once daily subcutaneous dose for 12 weeks plus resistance training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus resistance training</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo as a once daily subcutaneous dose for 12 weeks plus resistance training</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ghrelin</intervention_name>
    <description>Ghrelin</description>
    <arm_group_label>Ghrelin plus resistance training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline will be used as a placebo</description>
    <arm_group_label>Placebo plus resistance training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with three, four or five frailty criteria using the Fried frailty criteria

        Exclusion Criteria:

          1. Diabetes mellitus or fasting glucose ≥ 126 mg/dL

          2. Hospitalization for stroke, myocardial infarction, coronary artery bypass graft
             surgery, vascular surgery in the past six months.

          3. New York Heart Association Class III or IV congestive heart failure

          4. Therapy for cancer in the past 12 months, except non-melanoma skin cancer

          5. BMI ≥ 30 kg/m2

          6. Current use of corticosteroids other than topical, ophthalmic, and inhaled
             preparations

          7. Therapy with megestrol acetate or dronabinol within the last 6 weeks

          8. Thyroid stimulating hormone measured as &lt; 0.4 uIU/L or greater than 10uIU/L

          9. Abnormal liver function tests (LFTs &gt; 2x upper limit of normal)

         10. Hemoglobin &lt; 11g/dL

         11. Insulin-like growth factor-I (IGF-I) above the age-specific reference range

         12. History of surgery within the last 30 days

         13. Hip fracture of hip or knee replacement within the previous 6 months or unable to walk

         14. Deemed unsafe to participate by one of the study exercise therapists

         15. Undergoing physical therapy or an exercise program

         16. Unstable medical or psychological conditions or unstable home or food environment

         17. Cognitive deficit as defined by a Folstein Mini Mental State Exam score &lt; 24/30

         18. Depression (defined as a score of &gt; 11 on the Geriatric Depression Questionnaire)

         19. Out of town for &gt; 1 week during the 12 week study

         20. Residing outside of a 15 mile radius of University of Pennsylvania Health System
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne R. Cappola, M.D.,Sc.M.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania, Perelman School of Medicine, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical and Translational Research Center, University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-5160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 2, 2013</study_first_submitted>
  <study_first_submitted_qc>July 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2013</study_first_posted>
  <results_first_submitted>September 9, 2015</results_first_submitted>
  <results_first_submitted_qc>September 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 11, 2018</results_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Anne Cappola</investigator_full_name>
    <investigator_title>Division of Endocrinology, Diabetes, and Metabolism</investigator_title>
  </responsible_party>
  <keyword>Frailty</keyword>
  <keyword>Sarcopenia</keyword>
  <keyword>Weight Loss</keyword>
  <keyword>Exercise</keyword>
  <keyword>Aging</keyword>
  <keyword>Ghrelin</keyword>
  <keyword>Elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Frailty</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ghrelin Plus Resistance Training</title>
          <description>Ghrelin 7.5 mcg/kg as a once daily subcutaneous dose for 12 weeks plus resistance training
Ghrelin: 2:1 ratio placebo to ghrelin
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Plus Resistance Training</title>
          <description>Placebo as a once daily subcutaneous dose for 12 weeks plus resistance training
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ghrelin Plus Resistance Training</title>
          <description>Ghrelin 7.5 mcg/kg as a once daily subcutaneous dose for 12 weeks plus resistance training
Ghrelin: 2:1 ratio placebo to ghrelin
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Plus Resistance Training</title>
          <description>Placebo as a once daily subcutaneous dose for 12 weeks plus resistance training
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.2" spread="4"/>
                    <measurement group_id="B2" value="81.6" spread="5"/>
                    <measurement group_id="B3" value="81.5" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Short Physical Performance Battery (SPPB)</title>
        <description>The SPPB includes three components: gait speed on a 15-foot walk, standing balance testing, and time to rise from a chair 5 times. Each test is rated on a five-level categorical score, with 0 representing inability to complete the test and 4 representing the highest level of performance, and summed to create a score ranging from 0 to 12.</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ghrelin Plus Resistance Training</title>
            <description>Ghrelin 7.5 mcg/kg as a once daily subcutaneous dose for 12 weeks plus resistance training
Ghrelin: 2:1 ratio placebo to ghrelin
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Resistance Training</title>
            <description>Placebo as a once daily subcutaneous dose for 12 weeks plus resistance training
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Short Physical Performance Battery (SPPB)</title>
          <description>The SPPB includes three components: gait speed on a 15-foot walk, standing balance testing, and time to rise from a chair 5 times. Each test is rated on a five-level categorical score, with 0 representing inability to complete the test and 4 representing the highest level of performance, and summed to create a score ranging from 0 to 12.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="2.1"/>
                    <measurement group_id="O2" value="2.4" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment-associated Adverse Events</title>
        <description>Treatment-associated emergent adverse events, including clinically meaningful changes in laboratory measurements (IGF-1, HbA1c, fasting blood glucose, fasting insulin).</description>
        <time_frame>Twelve weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ghrelin Plus Resistance Training</title>
            <description>Ghrelin 7.5 mcg/kg as a once daily subcutaneous dose for 12 weeks plus resistance training
Ghrelin: 2:1 ratio placebo to ghrelin
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Resistance Training</title>
            <description>Placebo as a once daily subcutaneous dose for 12 weeks plus resistance training
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-associated Adverse Events</title>
          <description>Treatment-associated emergent adverse events, including clinically meaningful changes in laboratory measurements (IGF-1, HbA1c, fasting blood glucose, fasting insulin).</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Weight</title>
        <description>Change in weight from baseline to 12 weeks</description>
        <time_frame>Baseline to twelve weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ghrelin Plus Resistance Training</title>
            <description>Ghrelin 7.5 mcg/kg as a once daily subcutaneous dose for 12 weeks plus resistance training
Ghrelin: 2:1 ratio placebo to ghrelin
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Resistance Training</title>
            <description>Placebo as a once daily subcutaneous dose for 12 weeks plus resistance training
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight</title>
          <description>Change in weight from baseline to 12 weeks</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.5"/>
                    <measurement group_id="O2" value="0.88" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lean Body Mass</title>
        <description>Total lean body mass by dual energy x-ray absorptiometry</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ghrelin Plus Resistance Training</title>
            <description>Ghrelin 7.5 mcg/kg as a once daily subcutaneous dose for 12 weeks plus resistance training
Ghrelin: 2:1 ratio placebo to ghrelin
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Resistance Training</title>
            <description>Placebo as a once daily subcutaneous dose for 12 weeks plus resistance training
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lean Body Mass</title>
          <description>Total lean body mass by dual energy x-ray absorptiometry</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.8"/>
                    <measurement group_id="O2" value="1.0" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Muscle Strength</title>
        <description>One repetition max bench press</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ghrelin Plus Resistance Training</title>
            <description>Ghrelin 7.5 mcg/kg as a once daily subcutaneous dose for 12 weeks plus resistance training
Ghrelin: 2:1 ratio placebo to ghrelin
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Resistance Training</title>
            <description>Placebo as a once daily subcutaneous dose for 12 weeks plus resistance training
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Muscle Strength</title>
          <description>One repetition max bench press</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" spread="21"/>
                    <measurement group_id="O2" value="29" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Food Intake</title>
        <description>Change in food intake by 3-day food intake record</description>
        <time_frame>Baseline to 12 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ghrelin Plus Resistance Training</title>
            <description>Ghrelin 7.5 mcg/kg as a once daily subcutaneous dose for 12 weeks plus resistance training
Ghrelin: 2:1 ratio placebo to ghrelin
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Resistance Training</title>
            <description>Placebo as a once daily subcutaneous dose for 12 weeks plus resistance training
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Food Intake</title>
          <description>Change in food intake by 3-day food intake record</description>
          <units>kcal/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298" spread="127"/>
                    <measurement group_id="O2" value="-81" spread="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life</title>
        <description>Quality of life as assessed by short form 36 (SF-36), higher score indicates better quality of life, scale is 0-100 points</description>
        <time_frame>Baseline to 12 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ghrelin Plus Resistance Training</title>
            <description>Ghrelin 7.5 mcg/kg as a once daily subcutaneous dose for 12 weeks plus resistance training
Ghrelin: 2:1 ratio placebo to ghrelin
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Resistance Training</title>
            <description>Placebo as a once daily subcutaneous dose for 12 weeks plus resistance training
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life</title>
          <description>Quality of life as assessed by short form 36 (SF-36), higher score indicates better quality of life, scale is 0-100 points</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="13"/>
                    <measurement group_id="O2" value="4" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Frailty Status</title>
        <description>According to the Fried frailty criteria: Weight loss, exhaustion, low physical activity, slow walking speed, weakness, range 0 to 5, higher score indicates more frailty</description>
        <time_frame>Baseline to 12 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ghrelin Plus Resistance Training</title>
            <description>Ghrelin 7.5 mcg/kg as a once daily subcutaneous dose for 12 weeks plus resistance training
Ghrelin: 2:1 ratio placebo to ghrelin
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Resistance Training</title>
            <description>Placebo as a once daily subcutaneous dose for 12 weeks plus resistance training
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Frailty Status</title>
          <description>According to the Fried frailty criteria: Weight loss, exhaustion, low physical activity, slow walking speed, weakness, range 0 to 5, higher score indicates more frailty</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="3" upper_limit="4"/>
                    <measurement group_id="O2" value="3.4" lower_limit="3" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ghrelin Plus Resistance Training</title>
          <description>Ghrelin 7.5 mcg/kg as a once daily subcutaneous dose for 12 weeks plus resistance training
Ghrelin: 2:1 ratio placebo to ghrelin
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Plus Resistance Training</title>
          <description>Placebo as a once daily subcutaneous dose for 12 weeks plus resistance training
Resistance training: The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anne Cappola, MD</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-573-5359</phone>
      <email>acappola@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

